Compass Pathways (CMPS) Stock Rockets 30% on FDA Rolling Review and Priority Voucher

Key Highlights

• Compass Pathways shares climbed +30.18% during pre-market hours, touching $13.50
• First quarter adjusted EPS of -$0.30 exceeded analyst consensus of -$0.43
• FDA authorized rolling NDA submission and review process for COMP360 psilocybin treatment
• Company received Commissioner’s National Priority Voucher, which could accelerate review by 1-2 months
• Several Wall Street firms increased price targets, with consensus rating among 11 analysts at “Strong Buy”

Compass Pathways experienced a transformative Monday morning. The London-headquartered biotechnology firm saw its shares surge more than 30% in pre-market activity to $13.50 — significantly surpassing its previous 52-week peak of $11.28.

COMPASS Pathways plc, CMPS

The dramatic upward movement resulted from a convergence of three positive catalysts: better-than-anticipated quarterly results, a critical regulatory achievement from the FDA, and an uncommon priority designation.

Regarding financial performance, Compass posted first quarter adjusted earnings per share of -$0.30, outperforming Wall Street’s forecast of -$0.43. While still representing a loss, this level of outperformance carries significant weight in the clinical-stage biotechnology sector.

The more substantial development came from regulatory progress. The FDA authorized Compass to proceed with a rolling New Drug Application submission and review for COMP360, the company’s synthetic psilocybin treatment designed for treatment-resistant depression. This rolling review process has commenced.

Additionally, Compass was awarded a Commissioner’s National Priority Voucher. This special designation has the potential to shorten FDA review duration by one to two months — a substantial advantage at this advanced stage of development.

The company has already filed at least one of three NDA modules. Complete submission remains on track for the fourth quarter of 2026, with commercial launch preparations anticipated by the end of that year.

Wall Street Increases Confidence

Analyst firms moved swiftly to update their outlooks. TD Cowen confirmed its Buy recommendation. RBC Capital increased its price objective to $22 from $21, maintaining an Outperform stance while highlighting supportive regulatory conditions and robust clinical data. Maxim Group delivered the most aggressive adjustment, raising its target to $20 from $12. Morgan Stanley elevated its price target to $17 from $16 while retaining an Overweight rating.

Among 11 covering analysts, the consensus recommendation for CMPS stands at “Strong Buy.”

The regulatory landscape received additional support from a White House executive directive instructing the DEA to expedite rescheduling evaluations for psychedelic compounds that have completed Phase 3 clinical trials. Current regulatory framework allows DEA rescheduling review to proceed simultaneously with FDA evaluation.

Compass anticipates COMP360 will initially be reclassified to Schedule 2, with official rescheduling potentially occurring within days following FDA approval — a timeline that eliminates much of the regulatory ambiguity that has historically pressured the psychedelics sector.

The Road Ahead for COMP360

Part B results from the COMP006 Phase 3 clinical trial are anticipated during early third quarter 2026. This data release will draw considerable attention from investors and analysts.

Compass concluded the quarter holding $466 million in cash and cash equivalents, providing sufficient capital to fund operations through 2028. This financial cushion eliminates immediate capital-raising concerns.

Notably, the broader equity markets trended downward on Monday — both the S&P 500 and Nasdaq posted losses. The CMPS rally was driven purely by company-specific developments.

The biotechnology firm is also slated to participate in an upcoming investor conference, which could maintain visibility among institutional investment managers in coming weeks.

The post Compass Pathways (CMPS) Stock Rockets 30% on FDA Rolling Review and Priority Voucher appeared first on Blockonomi.